Xbrane Biopharma AB has announced that it will apply for the market approval of its Xlucane (ranibizumab) biosimilar to Lucentis, in Europe and the US, in the next 12 months. The company also plans to license the rights for the sale and marketing of Xlucane in Latin America, Japan and China.
Xbrane is trying to get market approval for Xlucane before Lucentis loses patent protection in the EU in July 2022
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?